Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | PDE2A | O00408 | 15/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399201 | 0.87 | RXRA (0.40) | RXRARXRBRXRGLRRK2PDE2A | |
| SCHEMBL21796642 | 0.86 | RXRA (0.48) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL22723516 | 0.85 | RXRA (0.44) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL21796464 | 0.84 | RXRA (0.47) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL28610289 | 0.84 | RXRA (0.47) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL21797139 | 0.84 | RXRA (0.44) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL28604377 | 0.83 | RXRA (0.46) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL21796750 | 0.83 | RXRA (0.46) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL21796688 | 0.82 | RXRA (0.47) | RXRARXRBRXRGLRRK2CYP4F2 | |
| SCHEMBL21797150 | 0.81 | RXRA (0.44) | RXRARXRBRXRGLRRK2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | RXRA 4652/4885RXRB 4413/4885RXRG 4409/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | RXRA 4559/4885RXRB 4482/4885RXRG 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.